Utilize GLP-1 receptor agonists in individuals diagnosed with T2DM and either established atherosclerotic cardiovascular disease (ASCVD) or at a heightened risk for ASCVD to mitigate the likelihood of myocardial infarction, stroke, or cardiovascular death, irrespective of A1C levels and other therapies targeting glucose or cardiovascular health. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.